National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

anti-PD-L1 monoclonal antibody MDX-1105
A fully human monoclonal antibody directed against the protein ligand PD-L1 (Programmed Death-1 Ligand 1) with immunomodulating and potential antineoplastic activities. Anti-PD-L1 monoclonal antibody MDX-1105 binds to PD-L1, blocking its binding to and activation of its receptor, PD-1 (Programmed Death 1), which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation in chronic infectious disease. PD-L1 is expressed broadly on hematopoietic and parenchymal tissues; PD-1, a transmembrane protein, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Code name:MDX-1105



Previous:anti-KIR monoclonal antibody 1-7F9, anti-myeloma cell surface antigen immunoconjugate BT-062, anti-p53 T-cell receptor-transduced peripheral blood lymphocytes, anti-PD-1 human monoclonal antibody MDX-1106, anti-PD-1 monoclonal antibody CT-011
Next:anti-PLGF monoclonal antibody TB-403, anti-PSCA fully human monoclonal antibody MK4721, anti-thymocyte globulin, antibody-drug conjugate CR011-vcMMAE, antineoplaston A10

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov